US/UK/Canada

Share

Pick a time period -
Tags ( Active)

The COLDPREV study: ColdZyme Mouth Spray reduces both the viral load and the number of sick days with common cold in infected individuals, compared with placebo

Enzymatica today reports positive results from a clinical pilot study on 46 individuals performed at the Ear, Nose and Throat Clinic at Skåne University Hospital in Lund, Sweden. In individuals who were infected with the common cold virus, ColdZyme Mouth Spray reduced both the viral load and the number of sick days with a cold compared with placebo. “These are very interesting and promising results. The COLDPREV study shows statistically significant results with ColdZyme Mouth Spray in terms of reduction of the viral load in the throat and number of sick days with common cold in infected

Enzymatica to commence clinical market-monitoring study for the prevention and shortening of upper airway infection

Enzymatica’s “COLDPREV” study will commence during the spring. The study – which is placebo controlled – is aimed at investigating the prevention and disease progression in subjects who become inoculated (infected) with the common cold virus. Enzymatica has received approval from the Regional Ethical Review Board in Lund for its ”COLDPREV” clinical study. The study is a randomized, double-blind, and placebo controlled market-monitoring investigation for the CE marked medical device product, ColdZyme® Mouth Spray. The purpose of the study is to deepen knowledge about the prevention and

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe